Department of Neurology, University Hospital Cleveland Medical Center, Cleveland, OH, USA; Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.
Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
Lancet. 2024 Feb 24;403(10428):731-740. doi: 10.1016/S0140-6736(24)00050-3. Epub 2024 Feb 9.
Multiple randomised trials have shown efficacy and safety of endovascular thrombectomy in patients with large ischaemic stroke. The aim of this study was to evaluate long-term (ie, at 1 year) evidence of benefit of thrombectomy for these patients.
SELECT2 was a phase 3, open-label, international, randomised controlled trial with blinded endpoint assessment, conducted at 31 hospitals in the USA, Canada, Spain, Switzerland, Australia, and New Zealand. Patients aged 18-85 years with ischaemic stroke due to proximal occlusion of the internal carotid artery or of the first segment of the middle cerebral artery, showing large ischaemic core on non-contrast CT (Alberta Stroke Program Early Computed Tomographic Score of 3-5 [range 0-10, with lower values indicating larger infarctions]) or measuring 50 mL or more on CT perfusion and MRI, were randomly assigned, within 24 h of ischaemic stroke onset, to thrombectomy plus medical care or to medical care alone. The primary outcome for this analysis was the ordinal modified Rankin Scale (range 0-6, with higher scores indicating greater disability) at 1-year follow-up in an intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT03876457) and is completed.
The trial was terminated early for efficacy at the 90-day follow-up after 352 patients had been randomly assigned (178 to thrombectomy and 174 to medical care only) between Oct 11, 2019, and Sept 9, 2022. Thrombectomy significantly improved the 1-year modified Rankin Scale score distribution versus medical care alone (Wilcoxon-Mann-Whitney probability of superiority 0·59 [95% CI 0·53-0·64]; p=0·0019; generalised odds ratio 1·43 [95% CI 1·14-1·78]). At the 1-year follow-up, 77 (45%) of 170 patients receiving thrombectomy had died, compared with 83 (52%) of 159 patients receiving medical care only (1-year mortality relative risk 0·89 [95% CI 0·71-1·11]).
In patients with ischaemic stroke due to a proximal occlusion and large core, thrombectomy plus medical care provided a significant functional outcome benefit compared with medical care alone at 1-year follow-up.
Stryker Neurovascular.
多项随机试验已经证明了血管内血栓切除术在治疗大面积缺血性中风患者中的疗效和安全性。本研究旨在评估这些患者接受血栓切除术的长期(即 1 年)获益证据。
SELECT2 是一项 3 期、开放标签、国际、随机对照试验,采用盲终点评估,在美国、加拿大、西班牙、瑞士、澳大利亚和新西兰的 31 家医院进行。纳入年龄在 18-85 岁之间、因颈内动脉或大脑中动脉第一段近端闭塞导致缺血性中风、非对比 CT 显示大缺血核心(Alberta 中风计划早期计算机断层扫描评分 3-5[范围 0-10,数值越低表示梗死面积越大])或 CT 灌注和 MRI 测量值大于 50mL 的患者,在中风发作后 24 小时内随机分配至血栓切除术加医疗护理组或单纯医疗护理组。主要终点为意向治疗人群在 1 年随访时的改良 Rankin 量表(范围 0-6,分值越高表示残疾程度越大)。该试验在 ClinicalTrials.gov(NCT03876457)注册,现已完成。
该试验在 352 例患者随机分组(178 例接受血栓切除术,174 例仅接受医疗护理)后 90 天随访时提前因疗效而终止,该试验于 2019 年 10 月 11 日至 2022 年 9 月 9 日进行。与单纯医疗护理相比,血栓切除术显著改善了 1 年改良 Rankin 量表评分分布(Wilcoxon-Mann-Whitney 优势概率为 0.59[95%CI 0.53-0.64];p=0.0019;广义优势比为 1.43[95%CI 1.14-1.78])。在 1 年随访时,接受血栓切除术的 170 例患者中有 77 例(45%)死亡,而接受单纯医疗护理的 159 例患者中有 83 例(52%)死亡(1 年死亡率相对风险为 0.89[95%CI 0.71-1.11])。
在因近端闭塞和大核心导致缺血性中风的患者中,与单纯医疗护理相比,血栓切除术加医疗护理在 1 年随访时提供了显著的功能结局获益。
Stryker Neurovascular。